Comparative Analysis of TNF-alpha, TNF-R1, and TNF-R2 in Patients with Low-impact Fractures Due to Osteoporosis

Abstract

Objective To analyze the serum levels of TNF-alpha and its TNF-R1 and TNF-R2 receptors in the blood of patients with low-impact fractures due to osteoporosis, comparing between genders and with healthy patients.

Methods The present study was conducted with a blood sample of 62 patients, divided into patients with osteoporosis and healthy patients. The results were obtained using the ELISA method. Cytokine concentrations were determined based on the absorbance values obtained.

Results Serum TNF-alpha levels were undetectable in female patients, while in males they were found only in one patient, with no significant difference. Similar results were found in the analyses of TNF-R1 and TNF-R2 levels, a significant increase in levels of TNF-alpha receptors in the groups of patients with osteoporosis compared with the control group in both sexes. There was no significant difference between the sexes in the dosage of both receptors within the group with osteoporosis. There was also a positive and significant correlation in the levels of TNF-R1 and TNF-R2 only in women.

Conclusion The significant increase in TNF-R1 and TNF-R2 levels in women with osteoporosis suggest that the release and expression of these receptors may be contributing differently to the development of osteoporosis in men and women.

Keywords

osteoporosis - tumor necrosis factor-alpha - receptors, tumor necrosis factor

Work developed in the Department of Orthopedics and Traumatology, Universidade de Uberaba, Uberaba, MG, Brazil

Publikationsverlauf

Eingereicht: 28. November 2021

Angenommen: 12. September 2022

Artikel online veröffentlicht:
29. Juni 2023

• Referências

• 1 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285 (06) 785-795
• 2 Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci 2006; 1092: 385-396
• 3 Gali JC. Osteoporose. Acta Ortop Bras 2001; 9 (02) 53-62
• 4 Michaud M, Balardy L, Moulis G. et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 2013; 14 (12) 877-882
• 5 Negishi-Koga T, Shinohara M, Komatsu N. et al. Suppression of bone formation by osteoclastic expression of emaphoring 4D. Nat Med 2011; 17 (11) 1473-1480
• 6 Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by emaphoring 3A. Nature 2012; 485 (7396): 69-74
• 7 Lacey DL, Timms E, Tan HL. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93 (02) 165-176
• 8 Simonet WS, Lacey DL, Dunstan CR. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89 (02) 309-319
• 9 Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12 (01) 17-25
• 10 Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281 (5381): 1305-1308
• 11 Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17: 331-367
• 12 Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997; 100 (06) 1557-1565
• 13 Abu-Amer Y, Ross FP, McHugh KP, Livolsi A, Peyron JF, Teitelbaum SL. Tumor necrosis factor-alpha activation of nuclear transcription factor-kappaB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of Ikappa Balpha. J Biol Chem 1998; 273 (45) 29417-29423
• 14 Kobayashi K, Takahashi N, Jimi E. et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191 (02) 275-286
• 15 Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275 (07) 4858-4864
• 16 Goeddel DV. Signal transduction by tumor necrosis factor: the Parker B. Francis Lectureship. Chest 1999; 116 (1, Suppl) 69S-73S
• 17 Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000; 275 (35) 27307-27310
• 18 Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab 2005; 288 (05) E1011-E1018
• 19 Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995; 5 (10) 392-399
• 20 Gardner EM, Murasko DM. Age-related changes in Type 1 and Type 2 cytokine production in humans. Biogerontology 2002; 3 (05) 271-290
• 21 Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296 (5573): 1634-1635
• 22 Sahin G, Ozturk C, Bagis S, Cimen OB, Erdogan C. Correlation of serum cytokine levels with axial bone mineral density. Singapore Med J 2002; 43 (11) 576-578
• 23 Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 2007; 18 (03) 148-153
• 24 Kim JG, Ku SY, Kim H, Chun SW, Suh CS, Choi YM. Relationship between circulating tumor necrosis factor system and bone mass before and after estrogen plus progestogen therapy. Menopause 2009; 16 (03) 534-538
• 25 Mullin BH, Prince RL, Dick IM. et al. Bone structural effects of variation in the TNFRSF1B gene encoding the tumor necrosis factor receptor 2. Osteoporos Int 2008; 19 (07) 961-968
• 26 Crane JL, Cao X. Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling. J Clin Invest 2014; 124 (02) 466-472